Intestinal gas–liquid interface

The intestinal gas–liquid interface represents the physical boundary between intraluminal gas and the surrounding liquid or mucosal layer within the gastrointestinal tract. This interface is not a molecular receptor or enzyme but serves as a critical physical target for surfactants and anti-foaming agents used to treat gastrointestinal distress (StatPearls: https://www.ncbi.nlm.nih.gov/books/NBK555931/). In various digestive disorders, gas produced by microbiota or aerophagia can become trapped in a stable foam of small bubbles, which increases intraluminal pressure and causes symptoms like bloating and abdominal pain (PubMed: https://pubmed.ncbi.nlm.nih.gov/15184813/). Drugs such as simethicone act directly at this interface by lowering surface tension, which destabilizes the film surrounding gas bubbles and allows them to coalesce into larger, more easily expelled volumes (PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Simethicone). Because the target is a physical interface rather than a biological pathway, these interventions typically lack systemic absorption and exhibit a high safety profile. This mechanism is primarily utilized in the management of functional dyspepsia, irritable bowel syndrome, and as a preparation for endoscopic procedures to improve visualization (NIH: https://medlineplus.gov/druginfo/meds/a682683.html).

Other names

Gas-liquid interfaceIntestinal bubble surfaceMucosal-gas interface

Reduction of surface tension at the gas-liquid interface to promote coalescence of gas bubbles.